<DOC>
	<DOC>NCT01244230</DOC>
	<brief_summary>Primary Objective: To evaluate safety (4 weeks) Secondary Objectives: - To evaluate the long-term safety (12 weeks) - To evaluate the efficacy - To characterize the pharmacokinetic profile</brief_summary>
	<brief_title>Safety, Efficacy and Pharmacokinetic Study of Allegra in Pediatric Patients With Atopic Dermatitis (AD)</brief_title>
	<detailed_description>The study consists of four phases: up to 9-day screening phase, main 4-week treatment phase, up-to 8-week extension phase, and up-to 5-day post-treatment phase.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Fexofenadine</mesh_term>
	<criteria>Inclusion criteria: Aged 6 months through 11 years Patients with atopic dermatitis Exclusion criteria: Main itching scores are 4 or less than 2 on last three consecutive days before registration. Patients who have itching only on face, head, or diaper area. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>